A phase 2 trial examining the use of small molecule immunomodulator EC-18 in patients with head and neck cancer experiencing chemoradiation-induced oral mucositis met its primary and secondary end points.
Patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer experienced a progression-free survival benefit after being treated with elacestrant.
Takayuki Yoshino, MD, PhD gives his perspective on the COLMATE trial and what it's done to help patients overcome colorectal cancer.
Investigators discuss the use of targeted therapies to treat metastatic colorectal cancer.
After reviewing implications of the MAIA study in multiple myeloma, experts consider unmet needs and future directions in care.
Panelists discuss the case of a 77-year-old man with newly diagnosed multiple myeloma who wishes to discontinue therapy after achieving a very good partial response.
Investigators compared tradeoffs in breast cancer screening strategies in Black patients vs White patients.
Patients with Bacillus Calmette-Guerin–unresponsive non-muscle invasive bladder cancer experienced a disease-free survival benefit when treated with intravesical Bacillus Calmette-Guerin and a novel IL-15 superagonist complex .
The FDA issued a complete response letter to the company responsible for developing narsoplimab because of the inability to estimate treatment effects on patients receiving hematopoietic stem cell transplant–associated thrombotic microangiopathy.